financetom
Business
financetom
/
Business
/
Nukkleus Stock Climbs: Acquisition Target Rimon Expected To Benefit From Iron Dome Deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nukkleus Stock Climbs: Acquisition Target Rimon Expected To Benefit From Iron Dome Deal
Nov 25, 2025 11:43 AM

Nukkleus Inc ( NUKK ) shares climbed Tuesday after the company said its planned acquisition, Rimon, stands to gain from a major Iron Dome expansion deal.

NUKK is among today’s top performers. Get the inside scoop here.

What Happened: Nukkleus ( NUKK ), which acquires and develops high‑potential aerospace and defense businesses, announced that Rimon — an Israeli supplier of critical power and subsystem components for the Iron Dome missile defense system — is expected to benefit significantly from Israel's newly approved expansion of the Iron Dome program.

On Nov. 20, 2025, Israel's Ministry of Defense signed a major deal with Rafael Advanced Defense Systems Ltd, one of Rimon’s key partners, to speed up production of Iron Dome interceptors and related equipment. The contract will be funded mostly by the U.S. defense aid package of $8.7 billion, which sets aside $5.2 billion for Israel's air-defense system, which is one of the biggest investments ever made in Iron Dome production.

Nukkleus ( NUKK ), through its controlling stake in Star 26 Capital Inc., is moving forward with the acquisition of Rimon, which has established strong partnerships with Rafael, Elbit Systems and other major defense partners. With new production now ramping up, Nukkleus ( NUKK ) expects strong demand for Rimon's manufacturing capabilities.

“This historic Iron Dome expansion contract validates our strategic decision to pursue the acquisition of Rimon, and position Nukkleus ( NUKK ) at the heart of Israel’s defense industrial base,” said Menny Shalom, CEO of Nukkleus ( NUKK ). “Rimon is already preparing to expand operations as early as 2026, and we expect the new production plan will have a significant impact on both Nukkleus ( NUKK ) and Rimon.”

NUKK Price Action: Nukkleus ( NUKK ) shares jumped 17.68% to hit $6.19 at the time of publication on Tuesday, according to Benzinga Pro. Despite today’s surge, the stock is still well below its 52-week high and is trading 12.3% below its 50-day moving average.

Read Next:

Nukkleus Lands $250 Million Funding Pact To Fuel Defense Tech Push

Image: Peshkova on Shutterstock.com

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mercadolibre to invest $135 million in storage and distribution center in Chile
Mercadolibre to invest $135 million in storage and distribution center in Chile
Aug 27, 2025
SANTIAGO, Aug 27 (Reuters) - Latin American e-commerce giant MercadoLibre ( MELI ) will invest $135 million in a new physical storage and distribution center in Chile, the company said on Wednesday in a statement. The 100,000-square-meter facility will be added to the company's logistic center in Colina, north of the country's capital, Santiago. ...
Looking At Kinross Gold's Recent Unusual Options Activity
Looking At Kinross Gold's Recent Unusual Options Activity
Aug 27, 2025
High-rolling investors have positioned themselves bullish on Kinross Gold ( KGCRF ) , and it's important for retail traders to take note. This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in KGC often signals that someone has privileged information. Today, Benzinga's...
--Capital One Securities Adjusts ConocoPhillips PT to $111 From $110, Maintains Equalweight Rating
--Capital One Securities Adjusts ConocoPhillips PT to $111 From $110, Maintains Equalweight Rating
Aug 27, 2025
01:01 PM EDT, 08/27/2025 (MT Newswires) -- Price: 98.32, Change: +1.27, Percent Change: +1.30 ...
Pfizer, BioNTech Get FDA Approval for Covid Vaccine
Pfizer, BioNTech Get FDA Approval for Covid Vaccine
Aug 27, 2025
01:00 PM EDT, 08/27/2025 (MT Newswires) -- Pfizer ( PFE ) and BioNTech (BNTX) said Wednesday the US Food and Drug Administration approved a supplemental license application for their LP.8.1-adapted monovalent COVID-19 vaccine for use in adults ages 65 and older and people ages 5 through 64 with at least one underlying condition that leaves them at high risk of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved